Noevir Holdings (4928) Fundamentals 2026 — P/E 19.4x, Revenue Analysis | SniperIQ
Noevir Holdings (4928) is a JP-listed Consumer Defensive company in Household & Personal Products with a market capitalization of ¥157.1B, trading at ¥4600.00 on the JPX. This SniperIQ fundamentals page covers Noevir Holdings's valuation (P/E 19.4x, P/B 3.2x), profitability (net margin 12.8%), revenue (¥64.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Noevir Holdings's market cap?
Noevir Holdings (4928) has a market capitalization of approximately ¥157.1B, trading at ¥4600.00 on the JPX. Market cap moves with the live share price.
What is Noevir Holdings's P/E ratio?
Noevir Holdings's trailing twelve-month P/E ratio is 19.4x, with a price-to-book (P/B) of 3.2x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
How profitable is Noevir Holdings?
Noevir Holdings runs a net profit margin of 12.8%, a gross margin of 67.0%, and an operating margin of 15.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Noevir Holdings generate?
Noevir Holdings reported revenue of ¥64.7B for fiscal year 2025, with net income of ¥8.0B and earnings per share (EPS) of 235.1. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Noevir Holdings pay a dividend?
Noevir Holdings offers a trailing dividend yield of about 5.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Noevir Holdings financially healthy?
Noevir Holdings carries a debt-to-equity ratio of 0.01x and a current ratio of 4.50x, with a market beta of 0.14. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Noevir Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Noevir Holdings (4928) the key facts are: market cap ¥157.1B, P/E 19.4x, revenue ¥64.7B, 52-week range 4190-4795. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.
Track Noevir Holdings's full fundamentals live
Get Noevir Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.